Global Bioenergies (ALGBE)

Business description

Global Bioenergies is in the scale-up stage to convert renewable resources into isobutene, the first of a number of olefins that will be licensed out to partners once the process is proved in an industrial pilot.

Stock data

Market cap.€73.3m
Last close€17.00
High / Low (52 weeks)€28.0 / €14.7
Stock market listingAL
Forecast net debt (€m)7.1
Forecast gearing ratio (%)146
SectorAlternative Energy

Price performance

Relative *(3.7668)2.583(50.4029)

* % Relative to local index

Other companies in sector Show

Company news

BRIEF-Global Bioenergies, Clariant and Ineos receive major EU funding to ...

Tue, 09 May 2017 15:56:15 GMT


Wed, 21 Dec 2016 16:30:00 GMT

Global Bioenergies Secures a 5.7 Million Euro Grant to Proceed with Its Second ...

Wed, 20 Nov 2013 16:41:15 GMT

Bioenergy can deliver cleaner future, says global report

Wed, 17 Jun 2015 14:03:45 GMT

Global Bioenergies SA (ALGBE) Dipped -1.69% on Oct 18

Wed, 18 Oct 2017 09:33:45 GMT

Investment summary

Global Bioenergies (GBE) has delivered impressive progress on its alternative olefins production technology. It is now entering the final phase of industrialisation and is on the verge of commercialisation. The company raised €10.25m on 30 June 2017 in order to complete the development and the industrialisation of the isobutene process, finance the detailed engineering studies of the IBN-One plant, launch the commercial roll-out and further diversify the raw materials available to the process. Our core valuation range is €34-51 per share.

Last updated on 03/10/2017

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2015A 2.2 (11.0) (12.2) (395.61) N/A N/A
2016A 3.3 (10.9) (12.4) (335.71) N/A N/A
2017E 3.7 (12.3) (15.7) (395.82) N/A N/A
2018E 3.7 (13.2) (16.7) (423.28) N/A N/A

Last updated on 13/09/2017

Latest video

Executive Interview - Global Bioenergies

Industry outlook

GBE is developing bioprocesses to convert renewable resources into some of the most widely used petrochemical building blocks. GBE's most advanced programme targets isobutene bioproduction. The company also targets the production of butadiene and propylene, which are presently at R&D stage.

Last updated on 03/10/2017

Key management

Marc Delcourt, CEO
Francois-Henri Sahakian, CFO

Company address

5 rue Henri Desbruères
+33 (0)1 64 98 20 50
View website